Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OlympiA adjuvant olaparib in germline BRCA-mutated HER2-negative high-risk primary breast cancer
NL-OMON47654Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Olaparib with Placebo (2 arms). Primary endpoint: Invasive Disease Free Survival. Started Feb 2015; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON47654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47654.